ImmunityBio valuation

IBRX · NASDAQ · USD

Compare ImmunityBio
$6.04Change from previous close: +0.25%Absolute change: +$0.02

Close · November 16, 2026

Valuation

The average price target of 4 analysts is $14.25.

Data as of November 15, 2026

ImmunityBio compared with similar companies

ImmunityBio's metrics compared with similar companies
MetricImmunityBioMedian25th–75th percentileBand
Price/sales35.18.806.44 – 14.5High
Gross margin98.8%91.1%59.7% – 95.3%High
Operating margin-150.2%11.5%-27.0% – 24.5%Low
Net margin0.0%0.0%-12.9% – 15.4%Middle
ROE122.9%8.3%-9.7% – 38.5%High
Debt/equity-1.170.120.02 – 0.67Low

Group: the stock and up to 10 companies in the same industry (with fewer than 5, related industries too), same region first, with a similar size. Band: low = the lowest quarter of values in the group, middle = 25th to 75th percentile, high = the highest quarter. Negative multiples and multiples above 500 are excluded; a comparison needs at least 5 values. The group is recalculated nightly.

TickerLandia analysisHow it is calculated

Companies in the group: same industry, similar size

Other metrics

Valuation multiples

Market cap
$6.4B
Enterprise value
$7.37B
P/E (trailing 12 months)
-8.70
Forward P/E
-54.7
Price/book
-8.53
EV/EBITDA
-28.6
EV/revenue
40.4

Profitability and growth

ROA
-30.4%
ROIC
-69.1%
Revenue growth (year over year)
52.3%
Earnings growth (year over year)
110.5%

Financial health

Total cash
$334.33M
Total debt
$1.3B
Current ratio
4.27
Quick ratio
3.96
Altman Z-Score
-9.35
Piotroski F-Score
2.00

Dividends

Dividend yield
0.0%

Analysts and estimates

Average price target
$14.25
Median price target
$14.50
High price target
$16.00
Low price target
$12.00
Analysts with a price target
4
Consensus
Strong buy
Forward EPS
-$0.11
EPS estimate, current year
-$0.93

Shares and trading

Beta
0.17
Average volume
12.64M
Shares outstanding
1.06B
Float
410.68M
Institutional ownership
20.5%
Insider ownership
62.1%
Short interest (% of float)
31.1%
Short ratio (days)
8.32